Adam advises healthcare providers, insurers, drug and device manufacturers, and related entities in matters concerning the Centers for Medicare & Medicaid Services (CMS), the Food and Drug Administration (FDA), the Health Resources and Services Agency (HRSA), and state health care programs. His knowledge of statutory interpretation and drafting expertise has been a resource to many clients as they navigate the legislative process.
Adam’s pro bono practice includes advancing health equity initiatives at the state level with efforts involving hospitals, payers, health centers, public health entities, and academic institutions. He is also one of the authors of the firm's Medicaid & the Law blog which highlights and explains current legal and policy issues in the Medicaid program.
Prior to joining the firm, Adam was an Assistant Counsel for the Office of the Legislative Counsel in the U.S. House of Representatives. He played a vital, non-partisan role for House leadership, key healthcare committees, and Members as a drafter of legislation relating to public and private healthcare programs from initial writing through enactment into law. He was responsible for advising on statutes, legislation, regulations, and policy issues concerning Medicare, Medicaid, CHIP, the Affordable Care Act, the 340B Drug Pricing Program, and related areas. Notably, he was a lead drafting counsel for efforts relating to prescription drug pricing reform (including portions of H.R. 3), portions of the No Surprises Act, numerous healthcare laws enacted in response to COVID-19, and COBRA continuation coverage.
During law school, Adam also obtained considerable policy, regulatory, and litigation experience with respect to the Federal healthcare programs through clerkships. He worked at the Finance Committee in the U.S. Senate, the CMS Division of the Office of General Counsel and the Office of Counsel to the Inspector General in the U.S. Department of Health and Human Services, and the U.S. Attorney’s Office for the District of Columbia.